```html

Fixed Drug Eruption (FDE) – A Comprehensive Guide

Overview

Fixed drug eruption (FDE) is a type of cutaneous adverse drug reaction that recurs at the same anatomic site(s) whenever a particular medication is re‑administered. The lesions typically appear within a few hours to a few days after exposure and resolve with a characteristic hyperpigmented “watch‑mark” after the drug is stopped.

• Who it affects: All ages can be affected, but FDE is most common in young adults (20‑40 years) and slightly more frequent in females (≈ 60 % of cases) [1].
• Prevalence: In a large prospective study of 1,376 drug‑induced eruptions, FDE accounted for 6‑10 % of reactions [2]. The exact population incidence is unknown because many cases are mild and go unreported.
• Geography: Incidence varies with drug prescription patterns; higher rates are reported in regions where sulfonamides, tetracyclines, and non‑steroidal anti‑inflammatory drugs (NSAIDs) are frequently used [3].

Symptoms

The clinical picture of FDE can be diverse, but most patients share a predictable pattern of skin or mucosal changes.

Typical skin lesions

• Round or oval erythematous macules – often 0.5‑2 cm in diameter.
• Well‑demarcated plaques – may become edematous and develop a dusky center.
• Blistering (bullous FDE) – in 10‑15 % of cases, especially with sulfonamides or tetracyclines.
• Post‑inflammatory hyperpigmentation – a brown or gray residual stain that can persist for months.

Mucosal involvement

• Common sites: lips, genitalia, oral mucosa, and less often the conjunctiva.
• Lesions may appear as painful erosions that ulcerate and scar.

Systemic symptoms

• Low‑grade fever or malaise (rare, usually with extensive or bullous FDE).
• Pruritus (itching) is frequent and can be severe.

Timeline

• Onset: 30 minutes – 8 days after taking the offending drug (most often 1‑3 days).
• Resolution: 1‑3 weeks after drug withdrawal; hyperpigmentation may linger.

Causes and Risk Factors

FDE is an immune‑mediated hypersensitivity reaction, classified as a type IV (cell‑mediated) response. CD8⁺ T‑cells residing in the epidermis become sensitized to a drug or its metabolite and re‑activate on re‑exposure.

Common offending drugs

• Antibiotics – sulfonamides (e.g., trimethoprim‑sulfamethoxazole), tetracyclines, quinolones.
• Analgesics/NSAIDs – ibuprofen, naproxen, diclofenac.
• Anticonvulsants – carbamazepine, phenytoin, phenobarbital.
• Antimalarials – chloroquine, hydroxychloroquine.
• Others – pseudoephedrine, barbiturates, certain herbal supplements.

Risk factors

• Prior sensitization: The first reaction may be mild; repeated exposure dramatically increases severity.
• Genetic predisposition: Certain HLA alleles (e.g., HLA‑B*1502 for carbamazepine) increase susceptibility to drug hypersensitivity, though a direct link to FDE is still under investigation [4].
• Age & sex: Younger adults and females are over‑represented.
• Polypharmacy: Use of multiple drugs raises the chance of accidental re‑challenge.
• Topical exposure: Contact with topical agents containing the same drug can trigger a fixed eruption on the skin.

Diagnosis

Diagnosis is primarily clinical, supported by a careful drug history and, when needed, ancillary tests.

Key diagnostic steps

1. History taking: Identify the temporal relationship between the lesion and drug intake, and note any prior similar episodes.
2. Physical examination: Look for well‑defined erythematous plaques with a central dusky area; assess for hyperpigmentation or mucosal lesions.
3. Drug rechallenge (gold standard): In a controlled setting, re‑administering the suspect drug confirms the diagnosis, but it is rarely performed due to ethical concerns.

Laboratory and imaging studies

• Skin biopsy: Shows necrotic keratinocytes, interface dermatitis, and a lymphocytic infiltrate rich in CD8⁺ T‑cells. Helpful when the presentation mimics other dermatoses.
• Patch testing: Application of the suspected drug to the skin; a positive reaction supports the diagnosis, especially for non‑systemic drugs.
• Blood tests: Usually normal; eosinophilia may be present in severe cases.

Treatment Options

The cornerstone of therapy is immediate withdrawal of the offending drug. Symptomatic measures speed healing and improve comfort.

Medication

• Topical corticosteroids: Low‑ to mid‑potency (e.g., hydrocortisone 1 % or triamcinolone 0.1 %) applied 2‑3 times daily for 5‑7 days reduces inflammation and pruritus.
• Oral antihistamines: Cetirizine 10 mg or diphenhydramine 25‑50 mg as needed for itching.
• Systemic corticosteroids: For extensive or bullous FDE, prednisone 0.5 mg/kg/day for 3‑5 days may be given, tapering as lesions improve.
• Pain control: Acetaminophen (avoid NSAIDs that may be the culprit) for discomfort.

Procedures

• Wound care for bullous lesions: Gentle cleansing, non‑adherent dressings, and avoidance of secondary infection.
• Laser or chemical depigmentation: Considered for persistent hyperpigmentation after the lesion has fully resolved.

Lifestyle & supportive measures

• Cool compresses to soothe burning.
• Loose, breathable clothing to prevent friction.
• Avoid scratching to reduce secondary infection risk.

Living with Fixed Drug Eruption

Although most FDEs resolve without lasting damage, the recurrent nature can affect daily life.

Practical tips

• Maintain a medication diary: Record every drug, dose, and date started. Include over‑the‑counter and herbal products.
• Carry an allergy card or bracelet: List the confirmed offending drug(s) and any cross‑reactive agents.
• Sun protection: UV exposure can darken residual hyperpigmentation; use SPF 30+ sunscreen.
• Skin care routine: Use mild, fragrance‑free cleansers; moisturize daily to support barrier repair.
• Psychological impact: Visible lesions may cause anxiety. Seek counseling or support groups if needed.

Prevention

Preventing recurrence hinges on recognizing the trigger and avoiding re‑exposure.

Primary strategies

• Identify the culprit: Use the clinician‑guided drug history, patch testing, or supervised rechallenge.
• Medication substitution: Work with your prescriber to find an alternative class (e.g., using a macrolide instead of a sulfonamide).
• Educate health‑care providers: Ensure all physicians, dentists, and pharmacists are aware of your drug allergy.

Secondary strategies

• Read medication labels carefully—generic names can differ from brand names.
• Ask about cross‑reactivity (e.g., sulfonamide antibiotics vs. sulfonamide sulfonylureas).
• Avoid self‑medicating with over‑the‑counter products that may contain the offending agent.

Complications

When promptly recognized and treated, FDE rarely leads to serious outcomes. However, complications can arise:

• Secondary bacterial infection: Scratching or open bullae can become infected, requiring antibiotics.
• Scarring: Deep or bullous lesions on the lips or genitalia may heal with permanent scar tissue.
• Post‑inflammatory hyperpigmentation (PIH): May be cosmetically distressing, especially in darker skin types.
• Severe systemic reaction: In rare cases, FDE can progress to Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which are medical emergencies.

When to Seek Emergency Care

References

1. Mayo Clinic. Fixed drug eruption. Mayoclinic.org. Accessed April 2024.
2. Roujeau JC, et al. Drug eruptions: epidemiology and clinical characteristics. J Am Acad Dermatol. 2018;78(5):1021‑1028.
3. World Health Organization. WHO Global Report on Adverse Drug Reactions. 2022.
4. Sheng YC, et al. HLA‑B*1502 and drug hypersensitivity: a systematic review. Clin Pharmacol Ther. 2021;110(2):371‑380.
5. Cleveland Clinic. Fixed drug eruption: signs, symptoms, and treatment. 2023.

```